Management of Newly Diagnosed and Uncontrolled Hypertension With Fixed-Dose Combination of Perindopril/Amlodipine and Perindopril/Indapamide/Amlodipine

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 471 participants.

Also called NCT03738761

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 471 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03738761
  • EudraCT 2017-001596-23
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Armenia, Croatia, Hungary, Poland, Russia, Serbia, Slovenia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03738761. Non-randomized; no masking; primary purpose treatment. Start 2018-02-13 (actual); primary completion 2019-09-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Management of Newly Diagnosed and Uncontrolled Hypertension With Fixed-Dose Combination of Perindopril/Amlodipine and Perindopril/Indapamide/Amlodipine
Acronym
PRECIOUS
Condition
Hypertension
Intervention (Drug)
Amlessa®
Intervention (Drug)
Co-Amlessa®
Lead sponsor
KRKA (class: industry)
Collaborator
Clinres Farmacija d.o.o. (class: industry)
Collaborator
University Medical Centre Ljubljana (class: other)

Record details

Record id
cardio:ct-nct03738761
Content hash
c1edae8839e8e8f302a62cdc23921b1c6f9d10143cadbe64bcaac0f36a8a33d0